ClinicalTrials.gg
RecruitingNCT07743710Updated Aug 12, 2026

The SMOKE Telehealth Study

An interventional study of Smoking and Health Telehealth Intervention 1 and Smoking and Health Telehealth Intervention 2 in Tobacco Smoking, sponsored by Binghamton University. Recruiting at 1 site in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-08-12.

Sponsored by Binghamton University · Not applicable, Interventional, and Treatment

Phase
Not applicable
Study type
Interventional
Enrollment
78
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Study summary

The goal of this clinical trial is to develop two health-focused interventions for tobacco smokers with chronic pain. The main questions it aims to answer are:

  • Are the interventions feasible for delivery via telehealth?
  • Are the interventions acceptable to participants?

This study has two phases. First, researchers will develop materials and receive feedback through three focus groups, updating the materials iteratively between each group. Next, researchers will compare the feasibility and acceptability of the two interventions.

Participants in the second phase will:

  • Complete the a single-session telehealth intervention online
  • Complete surveys online before, immediately after, and at 2-weeks, 1-month, and 3-months after the intervention session.
02

Conditions studied

  • Tobacco Smoking

Keywords

  • tobacco smoking
  • chronic pain
03

In context

Tobacco Smoking

264 studies on the registry are indexed under Tobacco Smoking; 42 are open to participants now.

This study's planned enrollment of 78 is below the median of 119 across 229 interventional studies indexed under Tobacco Smoking.

Browse Tobacco Smoking studies →

Lead sponsor

Binghamton University is the lead sponsor of 12 studies on the registry; 6 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • moderate to severe chronic pain
  • current daily tobacco smoking
  • willing and able to complete study components in English
  • adult (age 18 or over)

Exclusion criteria

Exclusion Criteria:

  • planning or currently attempting to quit
  • recent use of cessation treatments or other products to quit smoking
05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double (Participant, Outcomes assessor)
Enrollment
78 participants (estimated)

Study arms

  • Experimental
    Smoking and Health Intervention 1

    Behavioral: Smoking and Health Telehealth Intervention 1

  • Experimental
    Smoking and Health Intervention 2

    Behavioral: Smoking and Health Telehealth Intervention 2

Interventions

  • BehavioralSmoking and Health Telehealth Intervention 1

    The Smoking and Health Telehealth Intervention 1 provides educational information about how smoking is related to health and resources for smoking cessation. The intervention is delivered via live telehealth online in a single (30 minute) session.

  • BehavioralSmoking and Health Telehealth Intervention 2

    The Smoking and Health Telehealth Intervention 2 provides educational information about how smoking is related to health and resources for smoking cessation. The intervention is delivered via live telehealth online in a single (30 minute) session.

06

What researchers measure

Primary outcomes

  1. Recruitment Feasibility

    Enroll \>80% or more of people who meet eligibility criteria.

    Time frame: At the participant level, time from screening through enrollment is anticipated to be up to 4 weeks. The total will be calculated at the end of the entire enrollment period of the study, which is anticipated to be approximately 1 year and 9 months.

  2. Intervention Delivery Feasbility

    Delivery of the allocated intervention to at least 95% of enrolled participants.

    Time frame: At the participant level, intervention delivery occurs in the same session as enrollment. Overall feasibility will be assessed at the end of the entire enrollment period, which is anticipated to be 1 year and 9 months.

  3. Acceptability

    Mean scores for each item on the Client Satisfaction Questionnaire (CSQ) of 3 or greater. Mean total CSQ score of 24 or greater.

    Time frame: Immediately post intervention (at the end of the intervention session).

Secondary outcomes

  1. Cessation Motivation

    Separate ratings of motivation, importance, readiness, and confidence in quitting smoking on a scale from 0 (none) to 10 (100%).

    Time frame: Assessed immediately before and after the intervention (during the interventions session), and at 2-weeks, 1-month, and 3-months after the intervention session

  2. Motivation for Cessation Treatment

    Self-reported (yes/no) willingness to learn about cessation treatments and accept cessation resources, and intention to use cessation treatments.

    Time frame: Assessed immediately before and after the intervention (during the interventions session), and at 2-weeks, 1-month, and 3-months after the intervention session

  3. Cessation Treatment Engagement

    Self-reported (yes/no) use of cessation treatment.

    Time frame: 2-week, 1-month, 3-month follow-up

  4. Pain and Smoking Inventory

    The Pain and Smoking Inventory measures the extent to which people believe their smoking and pain are related.

    Time frame: Assessed immediately before and after the intervention (during the interventions session), and at 2-weeks, 1-month, and 3-months after the intervention session

  5. Pain and Smoking Questionnaire

    The Pain and Smoking Questionnaire measures the extent to which participants can correctly identify known associations between smoking and multiple health conditions.

    Time frame: Assessed immediately before and after the intervention (during the interventions session), and at 2-weeks, 1-month, and 3-months after the intervention session

07

Study locations

1 of 1 sites recruiting
08

References and documents

Individual participant data

Plan to share: Yes — De-identified self-report measures will be submitted to the National Institute of Mental Health Data Archive (NDA) at the National Institutes of Health.

Access criteria: Individuals will request access to the data via a data access request through the data archive.

No publications or documents are linked to this record.

09

Updates

Tracking since Sep 25, 2026
No changes since tracking began. The registry record was last updated on Aug 12, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT07743710
Lead sponsor
Binghamton University
Responsible party
Emily Zale (Assistant Professor, Binghamton University) — Principal investigator
First posted
Aug 4, 2026
Start date
Sep 1, 2026 (estimated)
Primary completion
Jul 2027 (estimated)
Completion
Jul 2027 (estimated)
Last update
Aug 12, 2026

Study contacts

Emily Zale
Contact
ezale@binghamton.edu
607-777-3381

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion